长春瑞滨和奥沙利铂在二线或三线转移性三阴性乳腺癌中的双周 II 期试验。
关键词: AE, adverse events ANC, absolute neutrophil count CBR, rate of clinical benefit CI, confidence interval CR, complete response ECOG, Eastern Cooperative Oncology Group ER, estrogen receptor FISH, fluorescence in situ hybridization HER2, human epidermal growth factor receptor 2 HR, hazard ratio IHC, immunohistochemistry IV, intravenously MBC, metastatic breast cancer ORR, overall response rate PR, partial response PgR, progesterone receptor SD, stable disease TNBC, triple-negative breast cancer TTP, time to progression ULN, upper limit of normal chemotherapy mTNBC, metastatic triple-negative breast cancer metastatic breast cancer oxaliplatin triple-negative vinorelbine
Mesh : Adult Aged Antineoplastic Combined Chemotherapy Protocols / adverse effects therapeutic use Disease Progression Drug Administration Schedule Female Humans Kaplan-Meier Estimate Middle Aged Neoplasm Metastasis Neoplasm Recurrence, Local Organoplatinum Compounds / administration & dosage Oxaliplatin Retreatment Treatment Outcome Triple Negative Breast Neoplasms / drug therapy mortality pathology Vinblastine / administration & dosage analogs & derivatives Vinorelbine
来 源:
DOI:10.4161/15384047.2014.986973
PDF(Pubmed)